New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export JNJ’s income statement to Excel — free account
Johnson & Johnson
JNJHealthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
270.20
3.10
+1.16%
Follow JNJ
Alert me
Johnson & Johnson 10-Q filed Jul 24, 2025
What changed
Part II, Item 1A, Risk Factors, against the 10-Q filed Apr 23, 2025: no comparison — the Item was not found